CDE Detailed Report
Disease: NeuroRehab
Subdomain Name: Disease-Specific Health-Related Quality of Life
CRF: Parkinson's Disease Quality of Life Scale (PDQUALIF)
Displaying 1 - 33 of 33
Subdomain Name: Disease-Specific Health-Related Quality of Life
CRF: Parkinson's Disease Quality of Life Scale (PDQUALIF)
Displaying 1 - 33 of 33
| CDE ID | CDE Name | Variable Name | Definition | Short Description | Question Text | Permissible Values | Description | Data Type | Disease Specific Instructions | Disease Specific Reference | Population | Classification (e.g., Core) | Version Number | Version Date | CRF Name (CRF Module / Guidance) | Subdomain Name | Domain Name | Size | Input Restrictions | Min Value | Max Value | Measurement Type | External Id Loinc | External Id Snomed | External Id caDSR | External Id CDISC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C17361 | Parkinson's Disease Quality of Life (PDQUALIF) - lightheaded scale | PDQUALIFLghtHdScale | Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Changing positions causes me to become lightheaded (lying to standing, or sitting to standing) | Never;Rarely;Sometimes;Occasionally;Always | Never;Rarely;Sometimes;Occasionally;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17393 | Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale | PDQUALIFSymp7DComp6MScale | Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days compared to 6 months ago, my Parkinson's symptoms are | Much better;Somewhat better;About the same;Somewhat worse;Much Worse | Much better;Somewhat better;About the same;Somewhat worse;Much Worse | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17372 | Parkinson's Disease Quality of Life (PDQUALIF) - positive outlook scale | PDQUALIFPositvOutlkScale | Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms make it hard to maintain a positive outlook | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17383 | Parkinson's Disease Quality of Life (PDQUALIF) - family friends view change scale | PDQUALIFFamFridViewChngScale | Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My spouse/children/friends' view of me has changed because of my illness | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17362 | Parkinson's Disease Quality of Life (PDQUALIF) - trouble balance scale | PDQUALIFTroubBalScale | Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form | When walking, I have trouble keeping my balance | Never;Rarely;Sometimes;Occasionally;Always | Never;Rarely;Sometimes;Occasionally;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17373 | Parkinson's Disease Quality of Life (PDQUALIF) - feel burden scale | PDQUALIFFeelBurdScale | Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms cause me to feel like a burden to other people | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17384 | Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale | PDQUALIFLesSexDesirblScale | Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | I feel I am less sexually desirable because of my illness | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17363 | Parkinson's Disease Quality of Life (PDQUALIF) - difficult swallowing scale | PDQUALIFDiffcltSwallScale | Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form | When eating or drinking liquids, I have difficulty swallowing | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17374 | Parkinson's Disease Quality of Life (PDQUALIF) - affected social life scale | PDQUALIFSocLfAffctedScale | Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms have affected my social life | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17385 | Parkinson's Disease Quality of Life (PDQUALIF) - hygiene independence 7 days scale | PDQUALIFHygienIndep7DaysScale | Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving, or toileting) I have been independent | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17364 | Parkinson's Disease Quality of Life (PDQUALIF) - communication ability scale | PDQUALIFCommunAbScale | Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms affect my ability to communicate with people | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17375 | Parkinson's Disease Quality of Life (PDQUALIF) - worry future scale | PDQUALIFWorryFutScale | Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form | I worry about what the future has in store | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17386 | Parkinson's Disease Quality of Life (PDQUALIF) - food preparation eating independent 7 days scale | PDQUALIFFoodPrepEatIndep7DScl | Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, in food preparation or eating I am independent | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17365 | Parkinson's Disease Quality of Life (PDQUALIF) - night wakeup bathroom scale | PDQUALIFNghtWakeBRScale | Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form | The need to go to the bathroom wakes me in the night | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17376 | Parkinson's Disease Quality of Life (PDQUALIF) - difficulty ask help scale | PDQUALIFAskHelpScale | Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Asking others for help is difficult for me | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17387 | Parkinson's Disease Quality of Life (PDQUALIF) - writing speaking problem 7 days scale | PDQUALIFWrtSpkProb7DScale | Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, written or spoken communication is a problem for me | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17366 | Parkinson's Disease Quality of Life (PDQUALIF) - affection ability scale | PDQUALIFAffectnAbScale | Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms affect my ability to show affection in intimate or sexual ways | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17377 | Parkinson's Disease Quality of Life (PDQUALIF) - independent important scale | PDQUALIFIndepImportScale | Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Maintaining my independence is important to me | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17388 | Parkinson's Disease Quality of Life (PDQUALIF) - fatigue participation problem 7 days scale | PDQUALIFFatigPartProb7DScale | Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, fatigue makes participation in activities, household chores, shopping or yard work a problem for me | Always;Frequently;Sometimes;Rarely;Never | Always;Frequently;Sometimes;Rarely;Never | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17367 | Parkinson's Disease Quality of Life (PDQUALIF) - aching limb scale | PDQUALIFAcheLimbScale | Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form | I have aching/burning/coldness/numbness in my hand/feet | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17378 | Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale | PDQUALIFDiffcltAdjtChngScale | Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form | It has been difficult to adjust to the changes which have taken place in my body | Very;Moderately;Somewhat;Slightly;Not at all | Very;Moderately;Somewhat;Slightly;Not at all | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17389 | Parkinson's Disease Quality of Life (PDQUALIF) - usual share interfered 7 days scale | PDQUALIFUsuSharInterf7DScale | Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, my Parkinson's symptoms interfere with my ability to do my usual share in the home | Always;Frequently;Sometimes;Rarely;Never | Always;Frequently;Sometimes;Rarely;Never | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17368 | Parkinson's Disease Quality of Life (PDQUALIF) - difficulty bladder control scale | PDQUALIFDiffcltBladContScale | Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form | I have difficulty with bladder control (frequency, urgency, inability) | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17379 | Parkinson's Disease Quality of Life (PDQUALIF) - social life not affected scale | PDQUALIFSocLfNotAffctedScale | Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms have not affected my social life | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17390 | Parkinson's Disease Quality of Life (PDQUALIF) - not sleep with spouse night 7 days scale | PDQUALIFNotSlpNghtWSpous7DScl | Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, my nighttime symptoms keep me from sleeping with my spouse/partner | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Everyday;5-6 Days;3-4 Days;1-2 days;Never | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17369 | Parkinson's Disease Quality of Life (PDQUALIF) - constipation scale | PDQUALIFConstipScale | Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Constipation is a problem | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17380 | Parkinson's Disease Quality of Life (PDQUALIF) - travel important scale | PDQUALIFTravelImportScale | Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Travel remains an important part of my leisure activities | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17391 | Parkinson's Disease Quality of Life (PDQUALIF) - driving interfered 7 days scale | PDQUALIFDrivInterf7DScale | Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, my Parkinson's symptoms have interfered with my driving ability | Doesn't Apply;Rarely;Sometimes;Frequently;Constantly | Doesn't Apply;Rarely;Sometimes;Frequently;Constantly | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17370 | Parkinson's Disease Quality of Life (PDQUALIF) - trouble fall asleep scale | PDQUALIFTroubFallAslpScale | Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms cause me to have trouble falling asleep, or waking early | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17381 | Parkinson's Disease Quality of Life (PDQUALIF) - family role affected scale | PDQUALIFFamRoleAffctedScale | Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms have affected my family role and relationship | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17392 | Parkinson's Disease Quality of Life (PDQUALIF) - financial strain 7 days scale | PDQUALIFFinancStrain7DaysScale | Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form | In the past 7 days, my illness has caused a financial strain for me and my family | Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly | Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17371 | Parkinson's Disease Quality of Life (PDQUALIF) - trouble stay asleep scale | PDQUALIFTroubStayAslpScale | Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form | I have trouble staying asleep | Never;Rarely;Sometimes;Frequently;Always | Never;Rarely;Sometimes;Frequently;Always | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
||||||||
| C17382 | Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale | PDQUALIFAwyFrmSocScale | Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form | My Parkinson's symptoms cause me to stay away from social gatherings | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree | Alphanumeric |
Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. |
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. | Adult | NeuroRehab Supplemental-Highly Recommended | 3.00 | 2013-07-18 09:11:50.26 | Parkinson's Disease Quality of Life Scale (PDQUALIF) | Disease-Specific Health-Related Quality of Life | Outcomes and End Points |
Single Pre-Defined Value Selected |
